In discussions with ViruSure they stated, "We are pleased to be involved in achieving this important milestone for Austrianova Singapore and Nuvilex that will enable the future development and evaluation of their treatment for pancreatic cancer." The ViruSure state-of-the-art facilities for amplifying cells under GLP (Good Laboratory Practices) conditions and their capabilities in testing for contaminants arena were contributing factors in it being chosen to carry out this activity.Dr. Robert F. Ryan, President and CEO of Nuvilex said, "We are very pleased by the thoroughness with which ViruSure has completed the first assessment and are now carrying out the amplification of these important cells for use in cancer treatments. The professionalism shown by both ViruSure and ASPL and the timely fashion in which this important milestone was achieved are extremely gratifying. Nuvilex is committed to advancing this project through the necessary additional clinical trials to the market place so that our novel pancreatic cancer treatment can be made available for the treatment of this devastating disease." About Nuvilex Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years. The company has been expanded to increase its natural product-based footprint and will continue to make advances as we move forward. We are an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. Our company's offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494 Safe Harbor Statement This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 firstname.lastname@example.org